Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Sees Significant Growth in Short Interest

Posted by ABMN Staff on Jul 3rd, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totaling 260,360 shares, an increase of 73.8% from the May 31st total of 149,795 shares. Currently, 8.3% of the company’s stock are sold short. Based on an average daily volume of 693,061 shares, the days-to-cover ratio is currently 0.4 days.

Valion Bio, Inc. Common Stock Price Performance

Shares of NASDAQ VBIO opened at $0.50 on Friday. Valion Bio, Inc. Common Stock has a 1-year low of $0.46 and a 1-year high of $5.60. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.31 and a quick ratio of 3.02. The business’s fifty day moving average price is $0.81 and its two-hundred day moving average price is $1.02. The firm has a market capitalization of $1.60 million, a PE ratio of -0.07 and a beta of 1.82.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock has an average rating of “Sell”.

View Our Latest Analysis on Valion Bio, Inc. Common Stock

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.